Related Experiment Video

Updated: Jun 20, 2026

In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
12:48

In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma

Published on: May 11, 2015

Microglial activation in Alzheimer's disease

Johannes C M Schlachetzki1, Michael Hüll

  • 1Center for Geriatrics and Gerontology Freiburg, University Hospital of Freiburg, Lehenerstr. 88, 79106 Freiburg, Germany. Johannes.schlachetzki@uk-erlangen.de

Current Alzheimer Research
|September 15, 2009
PubMed

Insights

Microglia, the brain's immune cells, play a complex role in Alzheimer's disease (AD). Their dual function in neuroinflammation and amyloid-beta plaque clearance offers potential therapeutic targets for this neurodegenerative condition.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no current disease-modifying treatments.
  • Amyloid-beta plaques are implicated as a key factor in AD pathogenesis.
  • Microglia, the brain's resident immune cells, are activated by amyloid-beta pathology.

Purpose of the Study:

  • To review the critical role of microglia in Alzheimer's disease.
  • To discuss microglia's involvement in neuroinflammation and amyloid-beta plaque clearance.
  • To explore the potential therapeutic implications of microglia and monocytes in AD.

Main Methods:

  • Literature review focusing on microglia and Alzheimer's disease research.
  • Analysis of the dual role of microglia (protective vs. detrimental).
  • Discussion of microglial receptors and their function in AD.

Main Results:

  • Microglia activation and recruitment are observed in response to amyloid-beta plaques.
  • Microglia exhibit a context-dependent dual role in AD, potentially being either harmful or beneficial.
  • Microglial receptors are crucial for managing neuroinflammation and clearing plaques.

Conclusions:

  • Microglia represent a significant factor in Alzheimer's disease progression.
  • Targeting microglia and their receptors may offer a disease-modifying strategy for AD.
  • Blood-borne monocytes, similar to microglia, may also influence AD pathology.

More Related Videos

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates09:12

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...